Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

Pediatric Rheumatology

Volumn 11, Issue 1, 2013, Pages

  Soybilgic, Arzu ^a   Onel, Karen B ^b   Utset, Tammy ^b   Alexander, Kenneth ^b   Wagner Weiner, Linda ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Human papillomavirus; Immunogenicity; Lupus; Pediatric; Safety; Vaccine

Indexed keywords

AZATHIOPRINE; BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; LUPUS ANTICOAGULANT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; SM ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; CHILD; CHRONICITY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLOW UP; GLOMERULOSCLEROSIS; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTERVENTION STUDY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE NECROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MYALGIA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PLEURISY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PRURITUS; RASH; SCHOOL CHILD; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS; URTICARIA; VACCINATION;

EID: 84881033152     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-11-29     Document Type: Article

References (35)

1. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
2. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004, 36(1):6-10. 10.1363/3600604, 14982671.
3. Cates W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American social health association panel. Sex Transm Dis 1999, 26(4 Suppl):S2-S7.
4. Revzina NV, Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 2005, 16(8):528-537. 10.1258/0956462054679214, 16105186.
5. Klumb EM, Pinto AC, Jesus GR, Araujo M, Jascone L, Gayer CR, Ribeiro FM, Albuquerque EM, Macedo JM. Are women with lupus at higher risk of HPV infection?. Lupus 2010, 19(13):1485-1491. Epub 2010 Jul 6, 10.1177/0961203310372952, 20605875.
6. Nyberg G, Eriksson O, Westberg NG. Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. Arthritis Rheum 1981, 24(5):648-650. 10.1002/art.1780240503, 7236321.
7. Blumenfeld Z, Lorber M, Yoffe N, Scharf Y. Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 1994, 3(1):59-61. 10.1177/096120339400300112, 8025589.
8. Dhar JP, Kmak D, Bhan R, Pishorodi L, Ager J, Sokol RJ. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 2001, 82(1):4-6. 10.1006/gyno.2001.6207, 11426953.
9. Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007, 57(4):619-625. 10.1002/art.22667, 17471531.
10. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000, 9(7):542-544. 10.1177/096120330000900711, 11035421.
11. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004, 31(9):1763-1767.
12. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004, 50(11):3619-3625. 10.1002/art.20616, 15529372.
13. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 2005, 53(5):781-784. 10.1002/art.21458, 16208671.
14. Bernatsky S, Ramsey-Goldman R, Gordon C, Joseph L, Boivin JF, Rajan R, et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatol (Oxford) 2004, 43(11):1386-1389.
15. Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfa E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007, 16(5):350-354. 10.1177/0961203307078225, 17576737.
16. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002, 34(2):147-153. 10.1086/338043, 11740700.
17. Lipnick RN, Karsh J, Stahl NI, Blackwelder WC, Schiffman G, Klippel JH. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 1985, 12(6):1118-1121.
18. Del Porto F, Lagana B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006, 24(16):3217-3223. 10.1016/j.vaccine.2006.01.028, 16466833.
19. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002, 21(5):369-372. 10.1007/s100670200099, 12223983.
20. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013, 72(5):659-664. 10.1136/annrheumdis-2012-201393, 22589375.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277. 10.1002/art.1780251101, 7138600.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992, 35(6):630-640. 10.1002/art.1780350606, 1599520.
23. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006, 66(9):1263-1271. discussion 1272-3, 10.2165/00003495-200666090-00008, 16827602.
24. Isenberg DA, Maddison PJ. Detection of antibodies to double stranded DNA and extracfigle nuclear antigen. J Clin Pathol 1987, 40(11):1374-1381. 10.1136/jcp.40.11.1374, 1141244, 3121680.
25. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987, 46(1):1-6. 10.1136/ard.46.1.1, 1002050, 3813670.
26. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115. 145272, 12522048.
27. Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis contribution of renal Histologic data. Am J Med 1983, 75:382-391. 10.1016/0002-9343(83)90338-8, 6351607.
28. Hiramatsu N, Kuroiwa T, Ikeuchi H, Maeshima A, Kaneko Y, Hiromura K, Ueki K, Nojima Y. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology 2008, 47:702-707. 10.1093/rheumatology/ken019, 18390590.
29. Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011, 63:865-874.5.
30. Petaja T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-aduvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011, 129:2147-2157. 10.1002/ijc.25887, 21190190.
31. Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, Sertoli MR, Balleari E, Racchi O, Messina M, Caltabiano G, Icardi G, Durando P, Marincola FM, Boccardo F, Ferrarini M, Ansaldi F, De Maria A. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011, 186(10):6044-6055. Epub 2011 Apr 15, 10.4049/jimmunol.1004095, 3530046, 21498665.
32. Puissant-Lubrano B, Rostaing L, Kamar N, Abbal M, Fort M, Blancher A. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients. Exp Clin Transplant 2010, 8(1):19-28.
33. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow-up study in a Danish cohort. Arthritis Rheum 2011, 63:3032-3037. 10.1002/art.30483, 21953088.
34. Elkayam O, Paran D, Burke M, Zakut V, Ben-Yitshak R, Litinsky I, Caspi D. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005, 38:493-496. 10.1080/08916930500285725, 16373254.
35. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen H, Deosaransingh K, Emery M, Liaw KL, Jacobsen SJ. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012, 271(2):193-203. 10.1111/j.1365-2796.2011.02467.x, 21973261.